conv.

All stories
BusinessQuiet 4d · day 5

Eli Lilly captures 70% of new Medicare weight-loss drug patients

CEO Dave Ricks says 700,000 seniors have started GLP-1 treatments since July, with Lilly's drugs dominating the market.

newest coverage 3d agosummary written 3d ago5 pieces1 likes & upvotes NewswiresMastodonGoogle News

What to know

  • 700,000 Medicare beneficiaries have started weight-loss drugs since July's launch of the Bridge program, with Eli Lilly capturing 70% of new patients through Zepbound and Foundayo.
  • Zepbound dominates among patients with highest body weight and health complications, while Foundayo attracts one-third of oral drug patients seeking convenience.
  • Lilly's market share has widened to 61% of the combined obesity and diabetes market compared with 39% for rival Novo Nordisk, signaling competitive advantage in the Medicare segment.

“What it has done for the broader drug category is what we had hoped.”

Dave Ricks, Eli Lilly CEO · Quartz/CNBC ↗ · Sep 20

Dave Ricks Eli Lilly CEOEli LillyEli Lilly Pharmaceutical manufacturerCenters for Medicare and Medicaid Services Program administrator

Eli Lilly captures 70% of new Medicare weight-loss drug patients
Quartz

How it unfolded 2 developments, newest first · click a bar or a number to jump articlesposts

Peak 3 pieces in two hours at Sep 21, 12 PM; 5 pieces over 5 days (4 articles · 1 post) Sep 21, 12 PM — 3 pieces · 2 articles · 1 post — Google News 1, Mastodon 1, Newswires 1Sep 21, 2 PM — quietSep 21, 4 PM — quietSep 21, 6 PM — quietSep 21, 8 PM — quietSep 21, 10 PM — quietSep 22, 12 AM — quietSep 22, 2 AM — quietSep 22, 4 AM — quietSep 22, 6 AM — quietSep 22, 8 AM — 1 piece · 1 article — Newswires 1Sep 22, 10 AM — quietSep 22, 12 PM — quietSep 22, 2 PM — 1 piece · 1 article — Google News 1Sep 22, 4 PM — quietSep 22, 6 PM — quietSep 22, 8 PM — quietSep 22, 10 PM — quietSep 23, 12 AM — quietSep 23, 2 AM — quietSep 23, 4 AM — quietSep 23, 6 AM — quietSep 23, 8 AM — quietSep 23, 10 AM — quietSep 23, 12 PM — quietSep 23, 2 PM — quietSep 23, 4 PM — quietSep 23, 6 PM — quietSep 23, 8 PM — quietSep 23, 10 PM — quietSep 24, 12 AM — quietSep 24, 2 AM — quietSep 24, 4 AM — quietSep 24, 6 AM — quietSep 24, 8 AM — quietSep 24, 10 AM — quietSep 24, 12 PM — quietSep 24, 2 PM — quietSep 24, 4 PM — quietSep 24, 6 PM — quietSep 24, 8 PM — quietSep 24, 10 PM — quietYesterday, 12 AM — quietYesterday, 2 AM — quietYesterday, 4 AM — quietYesterday, 6 AM — quietYesterday, 8 AM — quietYesterday, 10 AM — quietYesterday, 12 PM — quietYesterday, 2 PM — quietYesterday, 4 PM — quietYesterday, 6 PM — quietYesterday, 8 PM — quietYesterday, 10 PM — quietToday, 12 AM — quietToday, 2 AM — quietToday, 4 AM — quietToday, 6 AM — quietToday, 8 AM — quietToday, 10 AM — quietToday, 12 PM — quiet 12
Sep 22Sep 23Sep 24yesterdaynow · 1:38 PM ET
  1. 2

    Lilly's market dominance reflects strategic positioning within Medicare program

    Analysis shows Lilly's 70% capture of new Medicare patients extends its recent market gains. Foundayo, the oral pill, attracts one-third of new oral drug patients seeking convenience and smaller weight loss, while Zepbound dominates for patients with higher complications. Lilly's position has widened from roughly 61% of the combined obesity and diabetes market in Q2 compared with 39% for Novo.

    “The pill is better suited for patients who prefer a convenient treatment format and need to lose a smaller amount of weight.”
    — Dave Ricks
    1. 1 outlet Eli Lilly is capturing 70% of new Medicare patients on weight-loss drugs, CEO says

      first by Quartz, 4d ago

  2. 1

    Ricks reports 700,000 seniors on weight-loss drugs, 70% using Lilly products

    Eli Lilly CEO Dave Ricks told CNBC that since Medicare coverage launched in July, 700,000 seniors have entered the weight-loss drug market, with Lilly capturing seven out of every 10 new patients. Zepbound is the primary driver, directed toward patients with the highest body weight and health complications.

    “That's where Zepbound plays a big role.”
    — Dave Ricks
    1. 1 outlet Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

      first by CNBC, 4d ago

  3. background

    Medicare launches obesity drug coverage through Bridge program — Medicare begins covering weight-loss drugs under a temporary initiative called Bridge, with qualifying enrollees paying $50 per month. Available drugs include Zepbound and Foundayo from Eli Lilly and competing products from Novo Nordisk.